Other Solid Tumors Clinical Trials

6 recruiting

Other Solid Tumors Trials at a Glance

9 actively recruiting trials for other solid tumors are listed on ClinicalTrialsFinder across 6 cities in 7 countries. The largest study group is Phase 1 with 5 trials, with the heaviest enrollment activity in Houston, Nashville, and Boston. Lead sponsors running other solid tumors studies include CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Cogent Biosciences, Inc., and AstraZeneca.

Browse other solid tumors trials by phase

Treatments under study

About Other Solid Tumors Clinical Trials

Looking for clinical trials for Other Solid Tumors? There are currently 6 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Other Solid Tumors trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Other Solid Tumors clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 19 of 9 trials

Recruiting

NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry for Very Rare Solid Tumors

Solid TumorOther Solid TumorsVery Rare Tumors+2 more
National Cancer Institute (NCI)4,000 enrolled1 locationNCT07489378
Recruiting
Phase 2

A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement

Other Solid Tumors, AdultFGFR2 Gene Fusion/Rearrangement
Elevar Therapeutics30 enrolled19 locationsNCT07359820
Recruiting
Phase 1

Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors

Biliary Tract CancerEsophageal AdenocarcinomaGastric Adenocarcinoma+2 more
SystImmune Inc.160 enrolled17 locationsNCT07021066
Recruiting
Phase 1

A Study of DXC008 in Patients With Prostate Cancer and Other Solid Tumors

Prostate CancerEwing SarcomaOther Solid Tumors
Hangzhou DAC Biotechnology Co., Ltd.110 enrolled3 locationsNCT06926283
Recruiting
Phase 1

A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

Breast CancerOvarian CancerColorectal Carcinoma+4 more
AstraZeneca45 enrolled18 locationsNCT05877599
Recruiting
Phase 1

Phase I Clinical Study of BL-M07D1 in Locally Advanced or Metastatic Digestive Tract Tumors and Other Solid Tumors

Other Solid TumorsLocally Advanced or Metastatic Digestive Tract Tumors
Sichuan Baili Pharmaceutical Co., Ltd.26 enrolled1 locationNCT05631964
Recruiting
Phase 2

Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors

Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.350 enrolled1 locationNCT06947291
Recruiting
Phase 1Phase 2

A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors

CholangiocarcinomaAdvanced Solid TumorsIntrahepatic Cholangiocarcinoma (Icc)+9 more
Cogent Biosciences, Inc.110 enrolled15 locationsNCT06777316
Recruiting
Early Phase 1

Study of KRAS Neoantigen mRNA Vaccine (ABO2102) in Patients With KRAS -Mutated Solid Tumors

Pancreatic NeoplasmsOther Solid Tumors
Ruijin Hospital56 enrolled1 locationNCT06577532